中国证券报中证网讯(王珞)8月19日，无锡鑫宏业（301310）线缆科技股份有限公司(证券代码： 301310，证券简称：鑫宏业)发布公告称，公司与扬州曙光光电自控有限责任公司(以下简称"扬州曙光") 的股东方签署《交易框架协议》，拟以现金方式收购后者合计62%的股权。交易完成后，扬州曙光将成 为鑫宏业的控股子公司。 公开资料显示，扬州曙光成立于2002年，主营产品为伺服电机及驱动器，广泛应用于工业自动化等高端 应用领域。财务数据显示，扬州曙光2022年、2023年、2024年及2025年第一季度分别实现归母净利润 3566万元、3775万元、2062万元和455万元。 鑫宏业表示，公司主要从事新能源汽车、光伏、工业、核电等领域特种线缆的研发、制造与销售。公司 与扬州曙光产品属于上下游关系，此次收购符合公司向下游高附加值产品延伸的战略，有助于双方发挥 各自产品和渠道优势。公司将在保持线缆领域核心竞争力的同时，拓展业务至伺服电机及控制系统领 域，进一步增强公司盈利能力。 根据框架协议，鑫宏业将支付3000万元作为本次交易的定金，并根据股权转让协议的约定分期支付股权 转让款。转让方承诺扬州曙光2026—2028年 ...

本报（chinatimes.net.cn）记者于娜 北京报道 被实施退市风险警示（*ST）的南华生物医药股份有限公司（下称"南华生物"）近日紧急抛出"自救方 案"：公司正式公告筹划收购动作，目标直指湖南慧泽生物医药科技有限公司（下称"慧泽医药"）51% 股权，交易完成后标的公司将成为其控股子公司并纳入合并报表。 南华生物表示，通过并购慧泽医药，一方面有利于上市公司生物医药板块业务发展延伸，从而进一步增 强上市公司主营业务的盈利能力，提升上市公司抗风险能力；另一方面细胞临床转化研究和药物研发及 临床评价业务上具有较强的关联性，通过资产整合，将有利于提升公司经营效率，具有较强的协同效 应。 此次收购被市场普遍解读为南华生物应对退市风险的关键举措。据公司财报数据，南华生物已面临净利 润连续为负、营收规模不足的困境，2024年归母净利润亏损1984.6万元，全年营收仅1.34亿元，核心指 标触及退市警示标准，若2025年业绩仍无明显起色，退市压力迫在眉睫。 在此背景下，收购背后的潜在问题也成为资本市场关注焦点：南华生物当前现金流状况能否支撑现金交 易，收购后两家公司在业务、管理上的整合能否顺利推进，这些疑问将直接影响 ...

赛力斯（601127）（601127）发布公告称，控股子公司赛力斯汽车有限公司（赛力斯汽车）以公开摘牌 方式收购其控股子公司重庆金康动力新能源有限公司（金康动力）少数股东重庆科学城城市运营集团有 限公司持有的48.54%股权，交易价格为66345万元。本次交易完成后，赛力斯汽车持有金康动力股权由 51.46%，增加至100%。 据悉，金康动力主营产品为新能源汽车电机、电控系统。2024年，金康动力营业收入主要源于其旗下重 庆问界汽车销售有限公司及其子公司的汽车整车、汽车零部件销售收入408.71亿元。 公司表示，本次交易有助于提高上市公司整体经营决策效率，提升子公司之间的协同效应，实现经营效 益最大化。 ...

瑞财经 刘治颖 8月19日，羚锐制药(SH600285)发布2025年半年度报告，营收净利双增。 报告期内，羚锐制药实现营业收入20.99亿元，较上年同期增长10.14%；归属于上市公司股东的净利润4.74亿元，较上年同期增长14.85%。 据瑞财社查阅，羚锐制药董事长、总经理熊伟是一名80后，年薪百万。 熊伟，男，1984年12月生，EMBA，曾任上海复星医药产业发展有限公司市场营销部总经理助理，河南羚锐制药股份有限公司市场部总监、贴膏 剂销售部副总经理、副总经理等职。现任羚锐制药董事长、总经理。 东方财富数据显示，2020年至2024年，熊伟薪酬分别为160.2万元、177.2万元、177.3万元、180.5万元、183.5万元。 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 2024-12-31 | | | --- | --- | --- | --- | --- | | ■ 熊伟 160.2万 | 177.2万 | 177.3万 | 180.5万 | 183.5万 | | 行业平均 73.17万 | 83.81万 | 97.35万 | 119.3 ...

上海正帆科技股份有限公司（简称"正帆科技"，688596.SH）购买辽宁汉京半导体材料有限公司（简 称"汉京半导体"）股权的交易有了最新进展。 | 证券代码:688596 | 证券简称:正帆科技 | 公告编号:2025-053 | | --- | --- | --- | | 转债代码:118053 | 转债简称:正帆转债 | | 8月14日，正帆科技公告称，和汉京半导体5名股东签署了《股份转让协议》，通过股份受让的方式购买 汉京半导体62.2318%股权，交易金额合计为人民币 11.20亿元。交易完成后，汉京半导体将成为正帆科 技的控股子公司。 | 最终评估/估值结论 | 评估/估值价值:190,500.00(万元) | | --- | --- | | 评估/估值增值率:640. 46% | | | 评估/估值机构名称 江苏中企华中天资产评估有限公司 | | 正帆科技长期服务于集成电路、泛半导体、生物医药、新能源和先进制造业等高科技产业，并掌握超高 纯流体介质和系统相关的核心技术，提供设备类（CAPEX）业务和非设备类（OPEX）业务。 本次交易于7月8日晚公布。此次评估机构采用收益法进行估值，得出评估价值为 ...

为充分保障中小股东利益，经各方协商一致，本次交易的股份发行价格为8.77元/股，不低于公司定价基准日前120个交易日股票交 易均价的80%。 中国经济网北京8月19日讯据上交所官网，千金药业（600479）(600479.SH)发行股份购买资产于8月18日获重组委会议通过。 | 公司代码 ⇒ 公司简称 ｜ 板块 ｜ 业务类型 审核状态 | 独立财务顾问 律师事务所 会计师事务所 评估机构 更新日期 > 受理日期 > | | --- | --- | | 600479 千金药业 主板 发行股 重组委会议通过 国投证券股 湖南启元 天健会计师 - | 2025-08-18 2025-03-3 | | 份购买 | 份有限公司 律师事务 事务所 (特 | | 资产 | 所 殊普通合 | | 伏) | | 千金药业于8月8日披露的《发行股份及支付现金购买资产暨关联交易报告书(草案)(上会稿)》显示，本次交易方案包括发行股份购 买株洲国投及列邦康泰持有千金湘江药业合计28.92%的股权；发行股份及支付现金购买株洲国投及黄阳等21名自然人持有千金协 力药业合计68.00%的股权。 本次交易对方合计23名，其中发行股份购买资产 ...

智通财经APP获悉，中金发布研报称，考虑经营效率优化和股息收入增加，上调中国生物制药 (01177)2025/2026经调整净利润16.9%/17.2%至44.70亿元/49.21亿元。当前股价对应2025/2026年30.4 倍/27.2倍经调整市盈率。维持跑赢行业评级，同步上调目标价17.1%至8.90港元，对应34.2倍2025年市 盈率和30.6倍2026年经调整市盈率，较当前股价有12.5%的上行空间。 中金主要观点如下： 1H25业绩超出该行预期 1H25公司持续推进规模化、集中化和精细化管理，实现毛利率82.5%(YoY+0.4ppt)，销售管理费用率 42.9%(YoY-0.2ppt)，集团营销人员数同比下滑8.6%，主要企业营销人均产出同比提升21.8%，团队效率 稳步提升。 并购礼新制药，全球创新步伐进一步加快 公司创新管线围绕肿瘤、肝病代谢、呼吸感染和外科镇痛进行重点布局，并购礼新制药后，肿瘤领域布 局加速升级。1)肺癌全覆盖NSCLC：TQB2922(EGFR/c-Met双抗)即将开展NSCLC的III期临床， TQB6411(EGFR/c-Met双抗ADC)I期临床入组中，LM-16 ...

Core Viewpoint - The company, GanHua Technology (甘化科工), plans to acquire a 65% stake in Xi'an Ganxin Technology Co., Ltd. for 388 million RMB, marking a strategic entry into the optoelectronic imaging system sector [1][2][3]. Financial Performance - Ganxin Technology's main business includes the research, production, and sales of optoelectronic imaging systems and microcircuit modules, with projected revenues of 65.21 million RMB and 35.79 million RMB for 2024 and the first four months of 2025, respectively [6]. - The net profit for the same periods is expected to be 2.84 million RMB and 12.42 million RMB, indicating rapid growth [6]. - The performance commitment includes a net profit of no less than 35 million RMB in 2025 and a cumulative net profit of at least 85 million RMB from 2025 to 2026 [6]. Acquisition Details - The acquisition will result in goodwill formation, with an estimated increase of approximately 320 million RMB in goodwill on the balance sheet [7]. - The assessed value of Ganxin Technology is 601 million RMB, with an appraisal increment of 500.70 million RMB, reflecting a 499.22% increase [7]. Strategic Transition - GanHua Technology has transitioned from a sugar production focus to military and defense sectors since 2011, with a complete exit from sugar-related revenues by 2023 [10][14]. - The company previously acquired Sichuan Shenghua Power Technology Co., Ltd. for 660 million RMB, further solidifying its military industry presence [12][13]. Recent Performance Trends - The company's revenue has fluctuated significantly, with reported revenues of 540 million RMB, 445 million RMB, and 323 million RMB from 2021 to 2023, alongside a net profit swing from 31.86 million RMB to a loss of 23.3 million RMB in 2023 [15][16]. - In 2024, the company anticipates a revenue of 396 million RMB, a year-on-year increase of 22.58%, and a net profit of 20.51 million RMB, reflecting a 108.80% growth [17].

Core Viewpoint - Huakang Co., Ltd. plans to acquire 100% equity of Henan Yuxin Sugar Alcohol Co., Ltd. for 1.098 billion yuan, with an appraisal value increase of over 102%, significantly impacting the company [1][2] Group 1: Acquisition Details - The acquisition price of 1.098 billion yuan aligns closely with the appraisal value of 1.101 billion yuan, which represents an increase of approximately 556 million yuan from the book value of 545 million yuan [2] - The appraisal report by Kunyuan Asset Appraisal Co., Ltd. considered factors such as customer resources, sales networks, and product development capabilities, but did not disclose the identity of a major client referred to as "Company A" [3][4] Group 2: Client Relationship and Background - "Company A" is identified as a significant customer for Yuxin Sugar Alcohol, purchasing mainly xylitol and related products, and has connections to the third-largest customer, Lezhante, through Li Yubin, who is the vice president of Yuxin Sugar Alcohol [4][5] - Li Yubin has a long history in the sugar alcohol sales industry, previously working for Fudian Pharmaceutical, which is confirmed to be "Company A" [6][7] Group 3: Financial Issues of the Major Client - Fudian Pharmaceutical is facing severe debt issues, with multiple court cases and frozen bank accounts, raising questions about its ability to continue operations and its relationship with Yuxin Sugar Alcohol [7][8] - Despite ongoing production, Fudian Pharmaceutical's financial difficulties have led to a negative impact on its credit rating and operational capabilities [9] Group 4: Valuation Concerns - Questions arise regarding whether the appraisal of 1.1 billion yuan adequately considered the debt risks associated with Fudian Pharmaceutical, especially given its status as a major customer [10][11] - Kunyuan Appraisal stated that while they are aware of the legal issues, they do not disclose every detail in their reports, indicating a potential oversight in risk assessment [11][12] Group 5: Corporate Responses and Secrecy - Huakang Co., Ltd. has refrained from disclosing further information about the acquisition and the identity of "Company A," citing commercial confidentiality [16][17] - The company claims to have complied with disclosure regulations and maintains that the transactions are based on normal business needs [17]

Core Viewpoint - China Shenhua, a state-owned enterprise with a market value of 700 billion, announced that its stock will resume trading on August 18, following a significant acquisition plan involving multiple companies [1][2]. Group 1: Acquisition Details - China Shenhua plans to acquire 100% equity in 10 companies held by its controlling shareholder, China Energy Investment Group, and partial stakes in two other companies, through a combination of issuing A-shares and cash payments [2][3]. - The acquisition involves a total of 13 target companies, covering key sectors such as coal, coal power, and coal chemical industries, indicating a large-scale asset integration [4][6]. - The total assets of the acquired companies are estimated at 258.36 billion, with a net asset value of 93.89 billion [6]. Group 2: Financial Performance - The 13 companies involved in the acquisition are projected to generate a combined revenue of 125.996 billion and a net profit of 8.005 billion for the fiscal year 2024 [7]. - Among the target companies, five are expected to exceed 10 billion in revenue, including Xinjiang Energy, which houses the second-largest open-pit coal mine in China [7]. Group 3: Market Impact - The restructuring is anticipated to enhance China Shenhua's market position and facilitate a transition towards a greener and more intelligent coal industry through improved resource supply and logistics [8]. - Prior to the suspension, China Shenhua's A-share price was reported at 37.56 per share, with a total market capitalization of 746.3 billion [7]. Group 4: Profit Distribution - China Shenhua plans to distribute at least 75% of its net profit attributable to shareholders for the first half of 2025, which is estimated to be between 23.6 billion and 25.6 billion [10][11].